Analgesic Effect of Gabapentin in Total Knee Arthroplasty (TKA)
Analgesic Effect of Perioperative Gabapentin in Total Knee Arthroplasty: A Randomized, Double-blind, Placebo-controlled, Dose-response Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Aalborg, Denmark, 9000
- Dep. of ortopedic surgery, Aalborg Sygehus
-
Esbjerg, Denmark, 6700
- Dep. of ortopedic surgery, Esbjerg Sygehus
-
-
Hvidovre
-
Copenhagen, Hvidovre, Denmark
- Dep. of anesthesiology and ortopedic surgery Hvidovre Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Primary, unilateral total knee arthroplasty (TKA)
- Age 50-85 years
- Ethnic Danes
Exclusion Criteria:
- Treatment with gabapentins, systemic glucocorticoids, opioids, anxiolytic agents, antiepileptics or antidepressive agents (last 4 weeks)
- History of depression or mania
- History of alcohol or drug abuse
- History of malignancy
- History of epilepsia
- BMI > 40
- Disease affecting central or peripheral nerve function
- History of dementia
- History of renal insufficiency
- Allergy to Gabapentin
- Women with menstruation (last 2 years)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Gabapentin "high"
Tables with Gabapentin (1300 mg/day) for 7 days, starting on the day of surgery
|
Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
|
|
Active Comparator: Gabapentin "intermediate"
Tables with Gabapentin for 7 days (900 mg/day), starting on the day of surgery
|
Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
|
|
Placebo Comparator: Placebo
Placebo tablets for 7 days, starting on the day of surgery
|
Placebo tablets for 7 days, starting on the day of surgery
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain
Time Frame: At 24 hour
|
Pain during walking at 24 hour after surgery, visuel analog scale (VAS, 0-100 mm)
|
At 24 hour
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sedation
Time Frame: At 6 hours
|
Sedation at 6 hours, numeric range scale (NRS, 0-10)
|
At 6 hours
|
|
Pain
Time Frame: 1 week
|
Pain at rest and during walking the first week after TKA, visuel analog scale (VAS, 0-100 mm)
|
1 week
|
|
Cumulated pain scores
Time Frame: 1 week
|
Cumulated pain scores for pain the first week after TKA
|
1 week
|
|
Amount of rescue analgesic
Time Frame: 1 week
|
Amount of rescue analgesic the first week after TKA, mg
|
1 week
|
|
Side effects
Time Frame: 1 week
|
Side effects the first week after TKA
|
1 week
|
|
Cumulated side effects scores
Time Frame: 1 week
|
Cumulated side effects scores the first week after TKA
|
1 week
|
|
Amount of ondansetron and sleeping medicine
Time Frame: 1 week
|
Amount of ondansetron and sleeping medicine the first week after TKA, mg
|
1 week
|
|
Anxiety and depression
Time Frame: 1 week
|
Anxiety and depression - questionnaire - the first week after TKA, Hospitality and Anxiety and Depression Scale
|
1 week
|
|
Gabapentin level in blood-sample
Time Frame: 1 Day
|
Gabapentin level in blood-sample at 12 am on the first day after surgery, serum-koncentration
|
1 Day
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Torben B Hansen B Hansen, MD, Regionshospitalet Holstebro
- Study Director: Henrik Kehlet, MD, Rigshospitalet, Denmark
- Principal Investigator: Jørgen B Dahl, MD, Rigshospitalet, Denmark
- Principal Investigator: Per W Kristensen, MD, Vejle Sygehus
- Principal Investigator: Henrik Husted, MD, Hvidovre University Hospital
- Principal Investigator: Søren Solgaard, MD, Gentofte Hospital
- Principal Investigator: Mogens B Laursen, MD, Phd., Aalborg Sygehus
- Principal Investigator: Lars Hansen, MD, Esbjerg Sygehus
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Postoperative Complications
- Pain
- Neurologic Manifestations
- Pain, Postoperative
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Anti-Anxiety Agents
- Anticonvulsants
- Antimanic Agents
- Gabapentin
Other Study ID Numbers
Other Study ID Numbers
- THL-06-11
- 2011-003105-22 (EudraCT Number)
- H-4-2011-082 (Registry Identifier: Ethics Committee)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.